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Abstract
Angiogenesis, the formation of new blood vessels from pre-existing vascular beds, is essential for tumor growth, invasion,
and metastasis. Luteolin is a common dietary flavonoid found in fruits and vegetables. We studied the antiangiogenic
activity of luteolin using in vitro, ex vivo, and in vivo models. In vitro studies using rat aortic ring assay showed that luteolin
at non-toxic concentrations significantly inhibited microvessel sprouting and proliferation, migration, invasion and tube
formation of endothelial cells, which are key events in the process of angiogenesis. Luteolin also inhibited ex vivo
angiogenesis as revealed by chicken egg chorioallantoic membrane assay (CAM) and matrigel plug assay. Gelatin
zymographic analysis demonstrated the inhibitory effect of luteolin on the activation of matrix metalloproteinases MMP-2
and MMP-9. Western blot analysis showed that luteolin suppressed VEGF induced phosphorylation of VEGF receptor 2 and
their downstream protein kinases AKT, ERK, mTOR, P70S6K, MMP-2, and MMP-9 in HUVECs. Proinflammatory cytokines such
as IL-1b, IL-6, IL-8, and TNF-a level were significantly reduced by the treatment of luteolin in PC-3 cells. Luteolin (10 mg/kg/
d) significantly reduced the volume and the weight of solid tumors in prostate xenograft mouse model, indicating that
luteolin inhibited tumorigenesis by targeting angiogenesis. CD31 and CD34 immunohistochemical staining further revealed
that the microvessel density could be remarkably suppressed by luteolin. Moreover, luteolin reduced cell viability and
induced apoptosis in prostate cancer cells, which were correlated with the downregulation of AKT, ERK, mTOR, P70S6K,
MMP-2, and MMP-9 expressions. Taken together, our findings demonstrate that luteolin inhibits human prostate tumor
growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
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Introduction
Angiogenesis, the process by which capillaries sprout from
preexisting blood vessels, occurs in response to the increasing
demand for nutrients and oxygen experienced by proliferating
tumor cells. It plays a pivotal role in tumor growth, invasion and
metastasis and is tightly regulated by a large number of
proangiogenic and antiangiogenic factors. The angiogenic process
involves the activation, proliferation, and migration of endothelial
cells toward angiogenic stimuli produced by the tumor [1,2].
Induced secretion of angiogenic factors is commonly observed in
most aggressive tumors. Among various angiogenic factors, the
most essential is vascular endothelial growth factor (VEGF), which
exerts its mitogenic activity especially on endothelial cells [1].
VEGF exerts its biological effects by binding to its receptor
tyrosine kinases, expressed on endothelial cells. The biologically
relevant VEGF signaling events are mediated mainly via VEGF
receptor 2 (VEGFR2) [3]. Activation of VEGFR2 leads to the
activation of various downstream signal transduction proteins,
including extracellular signal-related kinase (ERK) [4,5], AKT [4],
mammalian target of rapamycin (mTOR) [6], and ribosomal
protein S6 kinase (p70S6K) [7], which promotes the growth,
migration, differentiation and survival of endothelial cells in pre-
existing vasculature.
Cytokines are low-molecular weight soluble proteins that
transmit signals between cells and are involved in several disorders.
Pro-inflammatory cytokines, including interleukin-1b (IL-1b),
interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis
factor-alpha (TNF-a) are involved in these pathological processes
[8]. Upregulation of these cytokines is closely linked to chronic
inflammation and cancer [9]. These cytokines could be prometa-
static or proangiogenic and their deregulated expression directly
correlates with the metastatic potential of several human
carcinomas [10]. There is a direct correlation between proin-
flammatory cytokines level and tumor angiogenesis. Increased
serum levels of proinflammatory cytokines such as IL-1b, IL-6,
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and TNF-a were found in tumor angiogenesis induced animals
[11]. Moreover altered levels of proinflammatory and proangio-
genic factors are observed in various forms of cancer [12].
Degradation of the extracellular matrix and basement mem-
brane is one of the first steps in angiogenesis. The matrix
metalloproteinases (MMPs) belong to a family of endopeptidases
that are capable of degrading basement membranes and
components of the extracellular matrix. Increased expression of
MMPs has been strongly implicated in tumor growth, invasion
and metastasis [13]. Among diverse proteolytic enzymes, gelati-
nases such as MMP-2 and MMP-9 play a key role in degrading
most ECM components surrounding tumor tissue [14] which are
expressed in elevated levels in proliferating endothelial cells [14].
Medicinal plants and phytochemicals are potential novel agents
for developing antiangiogenic drugs. Many studies have reported
the use of flavonoids as effective natural inhibitor on cancer
initiation and progression [15]. Luteolin (39,49,5,7-tetrahydroxy-
flavone, Fig. 1A) is a common dietary flavonoid found in fruits,
vegetables, and medicinal herbs. This compound possesses
a variety of anti-tumor properties, such as the inhibition of
proliferation and the induction of apoptosis [16,17]. Luteolin (Lut)
inhibited the migration and invasion of HGF-induced HepG2 cells
by suppressing the phosphorylation of c-Met, ERK, and Akt in
hepatoma [18] and it inhibited the invasion of cells in lung and
breast cancers [19].
In the present study, we analyzed the effect of luteolin on the
inhibition of tumor specific angiogenesis in vitro, ex vivo, and in vivo
models. Our results show that luteolin could significantly inhibit
VEGF-stimulated endothelial cell proliferation, chemotactic mi-
gration, invasion, tube formation, and tumor angiogenesis by
targeting VEGFR-2-regulated AKT/ERK/mTOR/P70S6K/
MMPs pathway, leading to the suppression of prostate tumor
growth and tumor angiogenesis. Luteolin also suppressed angio-
genesis as measured by chick embryo chorioallantoic membrane
(CAM) assay ex vivo and rat aortic ring assay in vitro. Moreover,
luteolin inhibited cancer growth by inducing apoptosis and
inhibiting angiogenesis in human prostate xenograft mouse model.
Materials and Methods
Ethics Statement
Animals were handled in strict accordance with good animal
practice as defined by Institutional Animal Care and Use
Committee (IACUC), University of Kentucky and this study was
carried out with their prior approval (Approval ID: 2011-0851).
Figure 1. Luteolin inhibited the VEGF induced cell proliferation in HUVECs. (a) Chemical structure of luteolin. (b) Effect of luteolin on
HUVECs viability in culture. Cell viability was quantified by MTT assay. Values are means 6 SD (mean of triplicate). *p,0.05 denotes a statistically
significant difference from untreated controls. (c) Luteolin inhibits the VEGF induced proliferation of endothelial cells. HUVECs were treated with
different concentrations of luteolin and VEGF for 48 h. Relative cell proliferation was determined by MTT assay. Values are means 6 SD (mean of
triplicate). *p,0.05 denotes a statistically significant difference from untreated controls; #p,0.05 denotes a statistically significant difference from
VEGF control.
doi:10.1371/journal.pone.0052279.g001
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Chemicals and Reagents
Luteolin (.99% pure) was purchased from Sigma (St. Louis,
MO, USA), dissolved in DMSO, aliquoted, and stored at 220uC.
Bacteria-derived recombinant human VEGF (121 a.a.) was
purchased from ProSpec-Tany TechnoGene Ltd. (Ness Ziona,
Israel). Growth factor-reduced Matrigel was purchased from BD
Biosciences (Bedford, MA). The antibodies anti-AKT, anti-
mTOR, anti-p70S6K1, antipoly (ADP-ribose) polymerase
(PARP), anti-cleaved caspase-3, phospho-specific anti-AKT
(Ser473), anti-mTOR (Ser2448), anti-p70S6K1 (Thr421/
Ser424), and anti-VEGFR2 (Tyr1175) were purchased from Cell
Signaling Technology (Beverly, MA). The antibodies against
phospho-specific ERK 1/2, ERK 1/2, MMP-2, MMP-9, and b-
actin were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA).
ELISA Kits
Highly specific quantitative ‘sand wich’ Elisa kits for human IL-
1b, IL-6, IL-8, and TNF-a were purchased from BioLegend, Inc.
(CA, USA) and the ELISA kit for VEGF was purchased from
RayBiotech (GA, USA).
Cell Lines and Cell Culture
HUVECs were purchased from American Type Culture
Collection (ATCC, Manassas, VA) and grown in Clonetics
Endothelial Cell Growth Medium-2 (EGM-2; Lonza, Walkersville,
MD). Human prostate cancer (PC-3) cells were purchased from
American Type Culture Collection and cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS).
Figure 2. Luteolin inhibited VEGF-induced migration, invasion, and tube formation of endothelial cells. (a) Luteolin inhibited HUVECs
migration. Cells were starved to inactivate cell proliferation and then wounded by pipette tips. EGM-2 with or without 10 ng/mL VEGF and different
dilutions of luteolin were added. Migrated cells were quantified by manual counting. (b) Luteolin inhibited HUVECs invasion. HUVECs with the
indicated concentrations of luteolin were seeded into the upper compartment of invasion chambers. The bottom chambers were filled with EGM-2
supplemented with VEGF. After 24 h incubation, migrated cells were fixed, stained and quantified. (c) Luteolin inhibited the tube formation of
HUVECs. HUVECs were treated with various dilutions of luteolin with VEGF for 24 h, cells were fixed, and tubular structures were photographed.
Values are means 6 SD (mean of triplicate). *p,0.05 denotes a statistically significant difference from untreated controls; #p,0.05 denotes
a statistically significant difference from VEGF control.
doi:10.1371/journal.pone.0052279.g002
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HUVECs and PC-3 cells were cultured at 37uC under a humid-
ified 95%: 5% (v/v) mixture of air and CO2.
Cell Viability Assay
HUVECs or PC-3 cells were seeded (5000 cells/well) in 96-well
flat bottomed titer plate and incubated for 24 h at 37uC in 5%
CO2 atmosphere. Different dilutions of luteolin were added and
incubated further for 48 h. Before 4 h completion of incubation,
10 ml MTT (5 mg/ml) was added [20]. The cultures were
solubilized and spectrophotometric absorbance was measured at
595 nm using a microtiter plate reader. The number of viable cells
was presented relative to untreated controls.
Figure 3. Luteolin inhibited ex vivo angiogenesis by CAM and matrigel plug assay and in vitro angiogenesis by rat aortic ring assay.
(a) Luteolin inhibits ex vivo angiogenesis in CAM assay. Fertile leghorn chicken eggs were candled on embryonic day 8; a small opening was made at
the top of the live eggs. Luteolin for treatment was mixed with 0.5% methyl cellulose in water and gently placed on the CAM. The eggs were
incubated for 48 h and photographed. Blood vessels density was quantified by Image J software and represented as a bar diagram. Values are means
6 SD (mean of triplicate). *p,0.05 denotes a statistically significant difference from untreated controls; #p,0.05 denotes a statistically significant
difference from 20 and 40 mmole/L luteolin. (b) Luteolin inhibits ex vivo angiogenesis in matrigel plug assay. Matrigel plug containg VEGF and luteolin
were implanted into the CAM at day 9 of fertilized chicken eggs. After 96 h of incubation, the matrigel plugs were taken out and dispersed in PBS and
incubated at 4uC overnight. Hemoglobin levels were determined using Drabkin’s reagent according to manufacturer instructions. Values are means6
SD (mean of triplicate). *p,0.05 denotes a statistically significant difference from untreated controls; #p,0.05 denotes a statistically significant
difference from VEGF control. (c) Luteolin inhibits microvessel outgrowth from the rat aortic ring. Dorsal aorta from a freshly sacrificed Sprague–
Dawley rat was cut into ,1 mm long pieces using surgical blade. Each ring was placed in a collagen pre-coated 96-well plate. VEGF, with or without
different dilutions of luteolin, was added to the wells. On day 6, the rings were analyzed by phase-contrast microscopy and microvessel outgrowths
were quantified and photographed. Values are means 6 SD (mean of triplicate). *p,0.05 denotes a statistically significant difference from untreated
controls.
doi:10.1371/journal.pone.0052279.g003
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Cell Proliferation Assay
HUVECs were seeded (5000 cells/well) in 96-well flat bottomed
titer plate and incubated for 24 h at 37uC in 5% CO2 atmosphere.
EGM-2 (0.5% FBS) containing 10 ng/mL VEGF with or without
different dilutions of luteolin was added and incubated for 48 h.
Relative cell proliferation was determined by MTT assay.
Wound-healing Migration Assay
HUVECs were grown into wells of collagen coated 24 well plate
dishes to 100% confluence. Cells were starved to inactivate cell
proliferation and then wounded by pipette tips. EGM-2 containing
0.5% FBS was added with or without 10 ng/mL VEGF and
different dilutions of luteolin. Images of the cells were taken after
24 h of incubation. Migrated cells were quantified manually, and
presented relative to untreated controls. Three independent
experiments were performed.
Collagen Matrix Invasion Assay
Collagen matrix invasion assay was performed as described
previously [2]. Briefly, HUVECs (105 cells/Transwell) along with
the indicated concentrations of luteolin were seeded into the upper
compartment of invasion chambers. The bottom chambers were
Figure 4. Luteolin inhibited the activation of VEGFR2-mediated signaling pathways. (a) Luteolin suppressed the activation of VEGFR2 and
their downstream signaling pathway triggered by VEGF in HUVECs. Proteins from different treatments was tested by Western blotting and probed
with specific antibodies. Experiments were repeated for three times. (b) Luteolin inhibits the MMP-2 and MMP-9 production by HUVECs. 1) Condition
medium from untreated HUVECs without trypsin activation. 2) Condition medium from untreated HUVECs after trypsin activation. 3) Condition
medium from untreated HUVECs after trypsin activation+EDTA. 4) Condition medium from pretreated HUVECs (40 mmol/L luteolin) after trypsin
activation. 5) Condition medium from pretreated HUVECs (20 mmol/L luteolin) after trypsin activation.
doi:10.1371/journal.pone.0052279.g004
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Figure 5. Luteolin inhibited cell viability, migration, and invasion of prostate cancer cells. (a) Luteolin inhibited cell viability of PC-3 cells.
Cell viability was quantified by MTT assay. Values are means 6 SD (mean of triplicate). *p,0.05 denotes a statistically significant difference from
untreated controls. (b) Luteolin inhibited VEGF secretion in PC-3 cells. VEGF level was estimated by ELISA method. Values are means 6 SD (mean of
triplicate). *p,0.05 denotes a statistically significant difference from untreated controls. (c) Luteolin inhibited PC-3 cells migration. Cells were starved
to inactivate cell proliferation and then wounded by pipette tips. Various dilutions of luteolin were added into the wells and incubated for 24 h;
migrated cells were quantified by manual counting. (d) Luteolin inhibited HUVECs invasion. HUVECs with the indicated concentrations of luteolin
were seeded into the upper compartment of invasion chambers. The bottom chambers were filled with serum-free RPMI. After 24 h incubation,
migrated cells were fixed, stained and quantified.
doi:10.1371/journal.pone.0052279.g005
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filled with 500 mL EGM-2 supplemented with 10 ng/mL VEGF.
After 24 h incubation, migrated cells were fixed with 3.7%
paraformaldehyde and stained with 0.5% crystal violet in 2%
ethanol. Membranes were washed and the dye was eluted with
10% acetic acid. Absorbance was measured at 595 nm using
a microtiter plate reader (Beckman coulter). The number of
invaded cells was presented relative to untreated controls.
Capillary-like Tube Formation Assay
HUVECs in medium EGM-2 were seeded into the matrigel
layer in 24–well plates at a density of 66104 cells/well along with
10 ng/ml VEGF. Various dilutions of luteolin were added into the
wells and incubated for 24 h at 37uC in 5% CO2 atmosphere.
Tube formation was examined and photographed using an
inverted microscope (20X) [21].
ELISA Assays for VEGF and Pro-inflammatory Cytokines
PC-3 cells (26105) were plated in 24-well plates and allowed to
attach by overnight incubation at 37uC. Cells were treated with
desired concentrations of luteolin for 24 h. Subsequently, the
culture media was collected and used to estimate the levels of
VEGF and pro-inflammatory cytokines such as IL-1b, IL-6, IL-8,
and TNF-a using commercially available kit according to the
manufacturers’ recommendations.
Rat Aortic Ring Assay
The rat aortic ring assay was used as the in vitro angiogenesis
study model [11]. Dorsal aorta from a freshly sacrificed Sprague–
Dawley rat was taken out in a sterile manner and rinsed in ice cold
PBS. It was then cut into ,1 mm long pieces using surgical blade.
Each ring was placed in a collagen pre-coated 96-well plate.
VEGF, with or without different dilutions of luteolin, was added to
the wells. On day 6, the rings were analyzed by phase-contrast
microscopy and microvessel outgrowths were quantified and
photographed [22]. The assay was scored from 0 (least positive)
to 5 (most positive) in a double-blind manner. Each data point was
assayed 6 times [23].
CAM Assay in Fertilized Chicken Eggs
The effect of luteolin on ex vivo angiogenesis was determined by
CAM assay. Briefly, fertile leghorn chicken eggs (Poultry Breeding
farm, University of Kentucky) were candled on embryonic day 8;
a small opening was made at the top of the live eggs. Luteolin for
treatment was mixed with 0.5% methyl cellulose in water and
gently placed on the CAM. The eggs were incubated for 48 h and
Figure 6. Luteolin inhibited pro-inflammatory cytokine production in PC-3 cells. Pro-inflammatory cytokines such as IL-1b, IL-6, IL-8, and
TNF-a level were estimated by ELISA method according to the manufacturers’ recommendations. (a) IL-1b, (b) IL-6, (c) IL-8, and (c) TNF-a. Values are
means 6 SD (mean of triplicate). *p,0.05 denotes a statistically significant difference from untreated controls.
doi:10.1371/journal.pone.0052279.g006
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photographed. Blood vessels density was quantified by Image J
software and represented as a bar diagram.
Matrigel Plug Assay
Fertilized chicken eggs (Poultry Breeding farm, University of
Kentucky) were incubated at 37uC for 9 days, and angiogenesis
Figure 7. Luteolin induced apoptosis in prostate cancer cells. (a) Cells were stained with Annexin V/PI, and apoptosis was determined using
flow cytometry. PC-3 cells were treated with various concentrations of luteolin for 48 h, after which apoptosis was determined by annexin V/PI
staining with flow cytometry. (b) Luteolin induced PC-3 cancer cell apoptosis by the cleaved-PARP and Caspase-3 analysis. PC-3 cells were treated
with luteolin for 48 h, and whole cell proteins were analysed by Western blotting with antipoly (ADP-ribose) polymerase (PARP) and anti-cleaved
caspase-3.
doi:10.1371/journal.pone.0052279.g007
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assay was performed as previously described [24]. In brief, VEGF
(100 ng) and luteolin (10 mg) were mixed with matrigel and
implanted into the CAM at day 9. After 96 h of incubation, the
tumor plugs were taken out and dispersed in PBS and incubated at
4uC overnight. Hemoglobin levels were determined using
Drabkin’s reagent (Sigma-Aldrich, St. Louis, MO) according to
manufacturer instructions.
Gelatin Zymography
SDS-PAGE was performed with 0.1% gelatin incorporated in
the separating gel [25]. HUVECs of subconfluent cultures were
incubated with serum free medium for 24 h at 37uC in 5% CO2
atmosphere. The conditioned medium was then collected and
subjected to zymographic analysis. Fifty microliters of sample
(equivalent to 100 mg protein) was activated with 5 ml trypsin
solution (75 mg/ml) in the presence and absence of luteolin (10, 20,
and 40 mM) in 100 mM Tris–HCl, 10 mM CaCl2 buffer (pH- 8.0)
and incubated for 1 h at room temperature. Samples were mixed
with an equal volume of 2X sample buffer and separated using
12% polyacrylamide gels containing 0.1% gelatin. The zymo-
grams were incubated in 100 mM Tris (pH-8.0), 10 mM CaCl2
for 12 h at 37uC followed by staining with Gelcode Blue stain
reagent for 2 h. Gels were destained to visualize the clear area
against the dark background.
Assessment of Apoptosis
The extent of apoptosis in prostate cancer cells was evaluated by
flow cytometric analysis using FITC conjugated Annexin V/
propidium iodide (BD PharMingen, San Diego, CA) staining
according to the manufacturer’s instructions. Both early apoptotic
(Annexin V-positive, PI-negative) and late apoptotic (Annexin V-
positive and PI-positive) cells were included in cell death
determinations.
Western Blot Analysis
To determine the effects of luteolin on the VEGFR2–dependent
mTOR signaling pathway, HUVECs were first starved in serum-
fee EGM-2 for 6 h, and then pretreated with or without luteolin
for 1 h, followed by the stimulation with 50 ng/mL of VEGF for
10 min (for VEGFR2 activation) or 30 min (for mTOR pathway
kinase activation). To examine mTOR pathway in prostate tumor
cells, normal cultured PC-3 cells were directly treated with
indicated dilutions of luteolin for 6 h. The total cellular samples
were washed twice with ice-cold PBS and lysed in 1X NuPAGE
LDS sample buffer supplemented with 50 mM dithiothreitol. The
protein concentration was determined using Coomassie Protein
Assay Reagent (Pierce, Rockford, IL). About 40 mg cellular
proteins were separated using 6%–12% SDS-polyacrylamide gel
and transferred to nitrocellulose membrane. Membranes were
blocked with 5% fat-free dry milk in 1X Tris-buffered saline (TBS)
and incubated with antibodies. Protein bands were detected by
incubating with horseradish peroxidase-conjugated antibodies
(Kirkegaard and Perry Laboratories, Gaithersburg, MD) and
visualized with enhanced chemiluminescence reagent (Perkin
Elmer, Boston, MA).
For tissue sections, radioimmunoprecipitation assay (RIPA)
buffer was added to the sections and homogenized with electric
homogenizer. After incubation for 20 minutes on ice, samples
were centrifuged for 30 minutes at 12,000 rpm at 4uC and
supernatant was collected as total cell lysate. SDS-PAGE was
carried out as described previously [26].
Xenograft Human Prostate Tumor Mouse Model
Six week old male BALB/cA nude mice were purchased from
Charles River Laboratories (Wilmington, MA). Animals were
housed in a specific pathogen-free room within the animal facilities
at the University of Kentucky, Lexington, KY. All animals were
allowed to acclimatize to their new environment for one week
prior to use and were handled according to the Institutional
Animal Care and Use, University of Kentucky. Mice were
randomly divided into 2 groups (5 animals/group). PC-3 cells
(56106 cells per mouse) were resuspended in serum-free RPMI-
1640 medium with matrigel basement membrane matrix (BD
Biosciences) at a 1:1 ratio (total volume: 100 mL) and then were
subcutaneously injected into the flanks of nude mice. After tumors
grew to about 100 mm3, mice were treated intraperitoneally with
or without luteolin (10 mg/kg/d). The body weight of each mouse
was recorded and tumor volume was determined by Vernier
caliper every day, following the formula of A6B260.52, where A is
the longest diameter of tumor and B is the shortest diameter. After
16 d, the mice were killed and solid tumors were removed.
Figure 8. Luteolin inhibited the activation of AKT/ERK/mTOR/
p70S6K/MMP-2/MMP-9 pathway in prostate cancer cells.
Luteolin inhibited the activation of AKT/ERK/mTOR/p70S6K/MMP-2/
MMP-9 pathway in PC-3 cells. Proteins from different treatments was
tested by Western blotting and probed with specific antibodies.
Experiments were repeated for three times.
doi:10.1371/journal.pone.0052279.g008
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Histology and Immunohistochemistry
Tumor tissues were fixed in 10% neutral-buffered formalin for
24 hours, processed, and embedded in paraffin blocks. The
sections (5 mm) were blocked with 10% goat serum and incubated
with a rabbit anti-CD31 (1:100; Novus Biologicals Inc, Littleton,
CO) and mouse ant-CD34 (1:100; BD Pharmingen Inc, San
Diego, CA) antibodies for 24 h. The slides were subsequently
incubated for 30 min with biotinylated anti-rabbit/anti-mouse
secondary antibody (Vector laboratories, Burlingame, CA) and
followed by incubation of Vectastain ABC Kit (Vector Labora-
tories). Diaminobenzidine (Sigma) was used as the chromagen and
methyl green (Sigma) as the counterstain.
Statistics
The values were presented as means6 SD. Two-way analysis of
variance (ANOVA) and Student’s t test were used for statistical
analysis. p,0.05 was considered significantly different.
Results
Effect of Luteolin on HUVECs Viability in Culture
Cell viabilty was determined by MTT assay. Effect of luteolin
on HUVECs viability in culture is shown in Figure 1B. luteolin
was found to be non-toxic to HUVECs at concentrations of 10–
40 mmol/L and these concentrations were used for further in vitro
experiments.
Luteolin Inhibited HUVECs Proliferation, Chemotactic
Migration, Invasion, and Tube Formation
HUVECs showed very high rate of proliferation when
stimulated with VEGF. Treatment with luteolin (10–40 mmol/L)
significantly inhibited VEGF induced proliferation of HUVECs
(Fig. 1C).
Cell migration is essential for angiogenesis in endothelial cell
[27]. Effect of luteolin on the chemotactic motility of HUVECs is
shown in Figure 2A. HUVECs migrated into the clear area when
stimulated with VEGF. Luteolin significantly inhibited the VEGF
induced migration of endothelial cells in a dose dependent
manner. Almost complete inhibition of endothelial cell migration
was observed at 40 mmol/L of luteolin which was comparable to
that at 0 h incubation. This concentration is non-toxic as is evident
from MTT assay (Fig. 1B) and hence the inhibitory effect could
not be attributed to cytotoxicity.
HUVECs showed a high invasive property through the collagen
matrix when stimulated with VEGF (Fig. 2B). Large numbers of
cells were found on the lower surface of the polycarbonate, but
Figure 9. Luteolin inhibited tumor growth in a xenograft mouse model. PC-3 cells were injected into 6-week old BALB/cA nude mice (56106
cells per mouse). After tumors grew to about 100 mm3, mice were treated intraperitoneally with or without luteolin (10 mg/kg/d). (a) Solid tumors in
the luteolin treated mice were significantly smaller than those in the control mice. Luteolin significantly reduced (b) tumor volume, and (c) tumor
weight, (d) but had no effect on the body weight of mice. Values are means 6 SD (mean of triplicate). *p,0.05 denotes a statistically significant
difference from untreated controls.
doi:10.1371/journal.pone.0052279.g009
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treatment with luteolin produced a significant inhibition in the
invasion of the collagen matrix by HUVECs in a dose dependent
manner.
Tube formation of endothelial cells is one of the key steps of
angiogenesis [27]. Treatment of HUVECs with luteolin signifi-
cantly inhibited tube formation (Fig. 2C). Incubation of HUVECs
on matrigel with VEGF resulted in the formation of elongated and
tube like structures which were effectively reduced by luteolin (20
and 40 mmol/L).
Luteolin Inhibited ex vivo Angiogenesis in CAM Assay
CAM assay was used to determine the antiangiogenic effect of
luteolin ex vivo. CAM revealed highly vascularized structure in the
control group (Fig. 3A). Exposure to luteolin (20 and 40 mmol/
egg) drastically reduced the vascular density which confirmed the
anti-angiogenic potential of luteolin through ex vivo assay.
Luteolin Inhibited ex vivo Angiogenesis in Matrigel Plug
Assay
To confirm the anti-angiogenesis effects of luteolin ex vivo,
matrigel plug assay was performed. As shown in Figure 3B,
luetolin (10 mg) significantly inhibited VEGF-induced angiogenesis
in the matrigel plug, indicating that luteolin effectively inhibited
angiogenesis ex vivo. Hemoglobin level was also significantly lower
in the luteolin treated matrigel plug, further confirming its
antiangiogeneic potential.
Luteolin Inhibited Microvessel Outgrowth from the Rat
Aortic Ring
The inhibitory effect of luteolin on angiogenesis in vitro was
assessed by aortic ring assay. VEGF induced microvessel out-
growth in rat aorta ring. As shown in Figure 3C, luteolin at 20 and
40 mmol/L inhibited micro-vessel growth after 6 days of in-
cubation, indicating that luteolin inhibits angiogenesis in vitro.
Luteolin Inhibited the Activation of VEGFR2-mediated
Signaling Pathways
Interaction of VEGFR2 with VEGF led to the activation of
various downstream signaling molecules responsible for endothe-
lial cell migration, proliferation, and survival [28]. To understand
the molecular mechanism of luteolin-mediated anti-angiogenic
properties, some key kinases involved in VEGFR2-mediated
Figure 10. Luteolin inhibited tumor growth and tumor angiogenesis in vivo by suppressing AKT/ERK/mTOR/p70S6K/MMP-2/MMP-9
pathway. (a) Luteolin inhibited the activation of AKT/ERK/mTOR/p70S6K/MMP-2/MMP-9 pathway in vivo. Proteins from tumor tissue was tested by
Western blotting and probed with specific antibodies. Experiments were repeated for three times. Luteolin inhibited tumor angiogenesis as evident
from (b) CD31 and (c) CD34 immunohistochemistry. Tumor sections (5 mm) were incubated with a rabbit anti-CD31 and mouse anti-CD34 antibodies
and were subsequently incubated with biotinylated anti-rabbit/anti-mouse secondary antibody, followed by staining with Vectastain ABC Kit.
doi:10.1371/journal.pone.0052279.g010
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signaling pathways were assayed using Western blotting. Luteolin
reduced phosphorylation of VEGFR2 in a dose-dependent
manner (Fig. 4A). Luteolin at 40 mM significantly inhibited the
activation AKT, ERK, mTOR, p70S6K, MMP-2, and MMP-9
(Fig. 4A), suggesting that luteolin exerted its anti-angiogenic
activity through regulating the activation of VEGFR2-mediated
downstream signaling cascade in endothelial cells. The concentra-
tions of luteolin used for the above experiments were found to be
non-toxic to endothelial cells (Fig. 1B), suggesting that the effect is
not through decreasing the cell viability.
Gelatin Zymography
The major forms of proteases detected by gelatin zymography
are type IV collagenases, MMP-2 and MMP-9 (Fig. 4B). Since
these proteases are secreted into the conditioned medium as
proenzymes (latent form requiring activation), an activation step
(trypsin activation) is necessary to get the MMPs activated.
Conditioned medium after trypsin activation showed digested
clear areas at 92 kDa and 72 kDa which were identical to MMP-9
and MMP-2 activity (Fig. 4B.2). Gels loaded with conditioned
medium without trypsin activation, did not show clear degradative
areas, indicating the inactive form of the enzyme (Fig. 4B.1).
Trypsin activated conditioned medium loaded gels, when in-
cubated with 10 mM EDTA (EDTA inhibits the proteolytic
activity by chelating Ca+) did not show clear degradative areas,
indicating that the enzyme responsible for degradation is
metalloproteinase (Fig. 4B.3). Conditioned medium treated with
luteolin at concentration of 40 mmol/L during trypsin activation
did not show any clear bands (Fig. 4B.4) suggesting that luteolin
inhibited the activation of procollagenase to active collagenase of
metalloproteinases. But luteolin at 20 mmol/L showed diminished
activation of metalloproteinases (Fig. 4B.5).
Luteolin Inhibited Cell Viability, Migration, and Invasion
of Prostate Cancer Cells
Effect of luteolin on cell viability toward PC-3 cells in culture is
shown in Figure 5A. At concentrations of 20–50 mmol/L luteolin
significantly reduced the cell viability of PC-3 cells in a dose
dependent manner.
Inhibition of tumor cell migration by luteolin is shown in
Figure 5C. Luteolin significantly inhibited the migration of PC-3
cells towards the scraped clear area in a dose-dependent manner.
Prostate cancer cells showed a very high invasive property
through the collagen matrix. Large numbers of cells were found in
the lower surface of the polycarbonate membrane, but treatment
with luteolin produced a significant inhibition in the invasion of
the collagen matrix by the tumor cells in a dose-dependent
manner (Fig. 5D).
Luteolin Inhibited VEGF and Pro-inflammatory Cytokine
Production in PC-3 Cells
VEGF plays an important role in angiogenesis by promoting
endothelial cell proliferation, migration, and differentiation [21].
The effect of luteolin on VEGF secretion and the results are shown
in Figure 5B. The luteolin treatment caused a dose-dependent and
statistically significant decrease in VEGF secretion. Effect of
luteolin on proinflammatory cytokines production is shown in
Figure 6. Luteolin significantly inhibited the production of IL-1b
(Fig. 6A), IL-6 (Fig. 6B), IL-8 (Fig. 6C), and TNF-a (Fig. 6D) by
PC-3 cells in culture.
Luteolin Potentiated Apoptosis in Prostate Cancer Cells
To determine whether the reduction of prostate cancer cell
viability is related to apoptosis, FACS analysis was carried out. PC-
3 cells were treated with various concentrations of luteolin (10–
40 mmol/L) for 24 h and subjected to flow cytometry analysis after
staining with annexin V-FITC and propidium iodide (PI). As
shown in Figure 7A, the percentages of apoptotic cells increased in
a dose-dependent manner.
To further verify the FACS analysis data, Western blotting
analysis was performed to examine caspase-3 and PARP cleavage
in cells treated with various concentrations of luteolin (20, 30,
40 mmol/L). Poly (ADP-ribose) polymerase (PARP) is a family of
proteins involved in cell death [29], which is cleaved into 89- and
24-kD fragments during drug induced apoptosis [28]. Caspase-3,
a member of the caspase family of 13 aspartate-specific cysteine
proteases that play a central role in the execution of the apoptotic
program [30,31], is primarily responsible for the cleavage of PARP
during cell death [32]. We found that treatment with luteolin (20,
30, 40 mmol/L) led to the activation of caspase-3 and subsequently
to the cleavage of PARP from its intact form (116 kD) to its
cleaved form (89 kD) markedly in PC-3 cells (Fig. 7B), Taken
together, these results suggest that luteolin induces apoptosis in
prostate cancer cells through a caspase-3-dependent pathway.
Luteolin Inhibited AKT/ERK/mTOR/P70S6K/MMPs
Pathway in PC-3 Prostate Cancer Cells
AKT/mTOR/p70S6K signaling has been identified as a novel,
functional mediator in angiogenesis [33,34]. ERK1/2, one of the
major targets of the mitogen-activated protein kinase (MAPK)
signaling pathway, has been implicated in the regulation of
angiogenesis for various functions including cell proliferation,
migration and survival [35]. MMPs-2 and 9 are over expressed in
many metastatic cancers and helps in the invasion of both tumor
and endothelial cells [36]. In this study, it was found that luteolin
supressed the activation of AKT, ERK, mTOR, P70S6K, MMP-
2, and MMP-9 in a concentration-dependent manner in PC-3
cancer cells (Fig. 8).
Luteolin Inhibited Tumor Angiogenesis and Tumor
Growth in vivo
Angiogenesis, the key step in tumor growth and metastasis,
provides necessary oxygen and nutrients for the tumor [37]. A
xenograft prostate tumor model was used to investigate the effect
of luteolin on tumor growth and angiogenesis. PC-3 prostate
cancer cells were injected (56106 per mouse) into the 6-week-old
male BALB/cA nude mice. After the tumors had developed (about
100 mm3), the mice were injected with or without 10 mg/Kg/day
luteolin (ip) every day (Fig. 9A). This intraperitoneal administra-
tion of luteolin significantly decreased tumor volume (Fig. 9B) and
tumor weight (Fig. 9C) but had no effect on the body weight of
mice (Fig. 9D). As shown in Figure 8B, tumors in control group
increased from 108.3167.35 to 551.66661.32 mm3, whereas
tumors in luteolin-treated group decreased from 102.97625.05 to
66.8464.72 mm3. The average weight of tumors from the control
group was 0.24260.04 gram whereas the average weight in
luteolin treated group was only 0.08260.03 gram, suggesting
strong anti-tumor potential of luteolin in xenograft mouse prostate
tumor model.
To further investigate whether luteolin inhibited tumor growth
by suppressing tumor angiogenesis, Western blot and immuno-
histochemical analysis of solid tumors were performed (Fig. 10).
Tumors from luteolin treated animals showed suppressed activa-
tion of AKT, ERK, mTOR, P70S6K, MMP-2, and MMP-9
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proteins (Fig. 10A). A large number of CD31 (Fig. 10B) and CD34
(Fig. 10C) positive cells were observed in untreated control group
whereas a small number in luteolin treated group. All these
observations indicate the antiangiogenic efficacy of luteolin.
Discussion
Tumors can grow up to ,2 mm size without requirement of
blood supply as diffusion is sufficient at this level to support the
removal of wastes from and supply of nutrients to tumor cells.
Therefore, the angiogenesis process is an important target to
suppress tumor growth and metastasis [38]. Angiogenic sprouting
of blood vessels is completed in three steps, namely, proliferation
of endothelial cells, breakdown of the extracellular matrix, and
migration of endothelial cells. The induction of this process is
mediated by angiogenic factors released by both tumor and host
cells, and depends on the net balance of positive and negative
regulators. These angiogenic factors bind to receptors on nearby
blood vessels and induce the activation, proliferation, and
migration of endothelial cells toward the tumor [39]. Accordingly,
inhibition of angiogenesis is an attractive approach to treat cancer
[40].
The degradation of the vascular basement membrane, which is
required for endothelial cell invasion, is performed by type IV
collagenases, called matrix metalloproteinases (MMPs) [41].
MMPs are a broad family of zinc-binding endopeptidases that
play a key role in the extracellular matrix (ECM) degradation
associated with cancer cell invasion, metastasis, and angiogenesis
[42]. MMPs degrade collagen and other extracellular matrix
components, disrupting the basement membrane barrier, and
enabling endothelial cells to migrate from preexisting vessels
toward angiogenic stimuli and to proliferate [43]. In particular,
MMP-2 and MMP-9 play an important role in the angiogenic
response as demonstrated in ECs (endothelial cells) as well as in vivo
animal models [44]. Overexpressions of MMP-2 and MMP-9 have
been demonstrated in human colorectal cancers [45]. Several
experiments have confirmed the key role of these enzymes in
angiogenesis [46,47]. These enzymes are secreted in inactive
proenzymatic forms, which require activation. It has been shown
that trypsin can activate pro-MMPs to active MMPs [48].
Luteolin significantly inhibited the endothelial cell proliferation,
invasion, migration, and tube formation. MMP-2 and MMP-9
expression and activation were downregulated by the treatment of
luteolin, similar results were observed by the treatment with
curcumin, another important naturally occurring compound [49].
In addition, luteolin treatment significantly inhibited neovascular-
ization ex vivo in CAM assay and matrigel plug assay. Luteolin also
exhibited cytotoxicity and induced apoptosis towards prostate
tumor cells (PC-3). In the present study we have found that
intraperitoneal administration of luteolin significantly decreased
volume and weight of tumors, but had no effect on the body
weight of mice. Immunohistochemical data was also showed that
the expressions of endothelial cell markers, CD31 and CD34 were
markedly less in tumor sections of luteolin treated animals.
Several inflammatory cytokines have been linked with tumor-
igenesis, which suggests that inflammation is associated with
cancer development [50]. Tumor necrosis factor (TNF)-a is
a potent pleiotropic proinflammatory cytokine produced by
macrophages, neutrophils, fibroblasts, keratinocytes, NK cells, T
and B cells, and tumor cells [51]. The role of TNF-a has been
linked to all steps of tumorigenesis, including cellular trans-
formation, promotion, survival, proliferation, invasion, angiogen-
esis, and metastasis [9]. Serum TNF-a level was found to be
elevated in cancer patients [52]. IL-1b is a proinflammatory
pleiotropic cytokine that has been shown to be an endogenous
mediator of various acute and chronic inflammatory conditions.
Furthermore IL-1b promotes the production of angiogenic
proteins from host stromal or infiltrating cells in tumor microen-
vironment enhancing tumor growth and metastasis [53,54].
Interleukin-6 (IL-6), a multifunctional cytokine, induces angiogen-
esis ex vivo and in vivo. In addition, in vitro studies have shown that
IL-6 is capable to increase endothelial permeability and stimulates
the proliferation of endothelial cells [55–57]. Interleukin-8 (IL-8)
has been shown to play an important role in tumor growth,
angiogenesis, and metastasis [58,59]. Luteolin treatment signifi-
cantly decreased the elevated levels of proinflammatory cytokines,
IL-1b, IL-6, IL-8, and TNF-a in PC-3 cells.
Activation of endothelial cells is initiated with binding of the
proangiogenic factors such as VEGF, FGF, PDGF to their
receptors followed by transduction of angiogenic signaling in the
cells [60]. VEGF is regarded as one of the earliest and important
signals to stimulate multistep cascade of tumor angiogenesis by
promoting endothelial cell proliferation and migration [61].
Luteolin significantly (P,0.05) inhibited the elevated level of
VEGF in PC-3 cells. VEGFR2 is essential for the morphogenesis
of vascular endothelium and is the primary receptor mediating the
angiogenic activity of VEGF through distinct signal transduction
pathways that regulate endothelial cell proliferation, migration,
differentiation and tube formation [62–64]. The VEGFR2
signaling pathway is a promising target of angiogenesis, because
it is a common pathway for tumor-induced angiogenesis [65].
VEGFR2 mediates the majority of the downstream effects of
VEGF in angiogenesis. Activation of VEGFR2 induced by VEGF
leads to the stimulation of various intracellular signaling cascades,
including activation of AKT, ERK, mTOR, and p70S6K
pathways [66,67]. Interruption of VEGFR2 signaling is thought
to be necessary for tumor angiogenesis and macroscopic solid
tumor growth [68]. In the present study, we have demonstrated
that luteolin is able to dramatically inhibit VEGF-induced
VEGFR2 activation.
AKT is a serine/threonine kinase that plays a central role in
a range of cellular functions including cell growth, proliferation,
migration, protein synthesis, transcription procedure and survival
and angiogenesis [69,70]. AKT regulates endothelial nitric oxide
(NO) synthase (eNOS) activation [71], which in turn stimulates
vasodilation, vascular remodeling and angiogenesis [70]. AKT
signaling stimulates the production of hypoxia inducible factor
a (HIFa) transcription factors, which mediates secretion of VEGF
and other growth factors which are important proangiogenic
factors [72,73]. The mammalian target of rapamycin (mTOR) is
a protein kinase of the PI3K/Akt signalling pathway with a central
role in the control of cell proliferation, survival, mobility and
angiogenesis. Dysregulation of mTOR pathway has been found in
many human tumors; therefore, the mTOR pathway is considered
an important target for the development of new anticancer drugs
[74]. One of the functions of Akt is phosphorylation and activation
of mTOR. Subsequently, activated mTOR regulates p70S6K
phosphorylation and activation [75].
The extracellular signal-related kinase 1/2 (ERK1/2), one of
the major targets of the mitogen-activated protein kinase (MAPK)
signaling pathway, has been implicated in the regulation of
angiogenesis for various functions including cell proliferation,
migration, and survival [35]. Upon the extracellular growth factor
stimulation, the activated ERK regulates its many substrates, such
as NF-kB and c-Jun, thereby regulating angiogenesis. ERK is also
necessary for eNOS activation [76]. P70S6K kinase (p70S6K) and
S6 ribosomal protein (S6RP) are proteins downstream of AKT,
and activation of p70S6K and S6RP stimulates protein synthesis
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and promotes cell growth and proliferation [77]. The present
study luteolin inhibited VEGF-dependent phosphorylation of
AKT, ERK, mTOR, and P70S6K in a dose dependent manner.
In conclusion, the present study shows that luteolin is a potent
inhibitor of angiogenesis in vitro, ex vivo and in vivo. Luteolin
treatment inhibited the activation of VEGF-R2 and thereby
suppressed the AKT/ERK/mTOR/P70S6K mediated angiogen-
esis signaling pathways.
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